Cas:51229-78-8 1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride manufacturer & supplier

Chemical Name:1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride

CAS.NO:51229-78-8

Synonyms:Quaternium-15;1-(cis-3-Chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride;Dowicil 200

Molecular Formula:C₉H₁₆Cl₂N₄

Molecular Weight:251.15600

HS Code:2933990090

Physical and Chemical Properties:

Melting point:178-210ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:9.72000

Exact Mass:250.07500

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1325 4.1/PG 2

Packing Group:

Contact us for information like Quaternium-15 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dowicil 200 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Quaternium-15 Use and application,Quaternium-15 technical grade,usp/ep/jp grade.

Related News: According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017). 1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride manufacturer According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017). 1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride supplier Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride vendor The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride factory Any drug or medication is composed of two components.